CANTIKA SALLINA N.A.S, - (2025) ANALISIS EFEKTIVITAS BIAYA PADA TERAPI PASIEN ANAK DENGAN DIABETES MELITUS TIPE I RAWAT JALAN DI RS. dr.SALAMUN TAHUN 2023-2024. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
![[img]](http://repository.stfi.ac.id/style/images/fileicons/text.png) |
Text
S_PSSF_A242005_Title.pdf Download (242kB) |
|
Text
S_PSSF_A242005_Chapter1.pdf Restricted to Repository staff only Download (69kB) |
|
Text
S_PSSF_A242005_Chapter2.pdf Restricted to Repository staff only Download (165kB) |
|
Text
S_PSSF_A242005_Chapter3.pdf Restricted to Repository staff only Download (84kB) |
|
Text
S_PSSF_A242005_Chapter4.pdf Restricted to Repository staff only Download (137kB) |
|
Text
S_PSSF_A242005_Chapter5.pdf Restricted to Repository staff only Download (50kB) |
|
Text
S_PSSF_A242005_Appendix.pdf Restricted to Repository staff only Download (336kB) |
Abstract
Diabetes melitus tipe I merupakan salah satu penyakit kronis pada anak yang insidensinya semakin meningkat di Indonesia. Penatalaksanaan penyakit ini membutuhkan terapi insulin jangka panjang yang menimbulkan beban biaya yang cukup besar, sehingga analisis efektivitas biaya sangat penting dilakukan. Penelitian ini bertujuan untuk mengetahui pola penggunaan obat insulin serta menganalisis efektivitas biaya terapi diabetes melitus tipe I pada pasien anak di RS. dr. Salamun Bandung periode Januari 2023 – Desember 2024. Penelitian menggunakan desain non-eksperimental dengan metode deskriptif dan pengambilan data retrospektif melalui data rekam medis elektronik. Sampel penelitian berjumlah 24 pasien anak dengan kriteria inklusi yang sesuai. Analisis biaya langsung menunjukkan rata-rata penggunaan Levemir sebesar Rp22.652.889 dengan efektivitas 37,5%, sedangkan Novorapid sebesar Rp29.414.400 dengan efektivitas 62,5%. Nilai ACER menunjukkan Levemir lebih rendah, yaitu Rp5.280.394, dibandingkan Novorapid Rp6.366.753. Sedangkan, analisis Incremental Cost Effectiveness Ratio (ICER) sebesar Rp20.489.427 memperlihatkan bahwa Novorapid meskipun lebih mahal, memiliki efektivitas klinis yang lebih tinggi. Kesimpulan penelitian yaitu terapi insulin levemir lebih efesien dari sisi biaya, sedangkan Novorapid unggul dalam efektivitas klinis. Dengan demikian, Levemir lebih disarankan dari sisi efisiensi ekonomi, sedangkan Novorapid lebih sesuai bagi pasien yang membutuhkan kontrol glukosa darah yang cepat dan optimal. Pemilihan terapi sebaiknya mempertimbangkan kondisi klinis pasien dan kemampuan ekonomi keluarga. ------- Type I diabetes mellitus is one of the chronic diseases in children whose incidence is increasing in Indonesia. Management of this disease requires long-term insulin therapy, which incurs significant costs, making cost-effectiveness analysis very important. This study aims to determine the pattern of insulin use and analyze the cost-effectiveness of type I diabetes mellitus therapy in pediatric patients at Dr. Salamun Hospital in Bandung from January 2023 to December 2024. The study used a non-experimental design with a descriptive method and retrospective data collection through electronic medical records. The study sample consisted of 24 pediatric patients who met the inclusion criteria. Direct cost analysis showed that the average cost of Levemir was IDR 22,652,889 with an effectiveness of 37.5%, while Novorapid cost IDR 29,414,400 with an effectiveness of 62.5%. The ACER value showed that Levemir was lower, at IDR 5,280,394, compared to Novorapid at IDR 6,366,753. Meanwhile, the Incremental Cost Effectiveness Ratio (ICER) analysis of IDR 20,489,427 showed that Novorapid, although more expensive, had higher clinical effectiveness. The conclusion of the study is that Levemir insulin therapy is more cost-effective, while Novorapid excels in clinical effectiveness. Therefore, Levemir is more recommended from an economic efficiency perspective, while Novorapid is more suitable for patients requiring blood glucose control.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Uncontrolled Keywords: | Diabetes Melitus Tipe I, Insulin, Analisis Efektivitas Biaya, ACER, ICER. ------ Type I Diabetes Mellitus, Insulin, Cost-Effectiveness Analysis, ACER, ICER |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine |
| Divisions: | Program Studi S1 Farmasi |
| Depositing User: | pustakawan - - |
| Date Deposited: | 20 Nov 2025 02:48 |
| Last Modified: | 20 Nov 2025 02:48 |
| URI: | http://repository.stfi.ac.id/id/eprint/3517 |
Actions (login required)
 |
View Item |
